NCT00430846 2014-12-18
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Seagen Inc.
Phase 1 Completed
Clinical Trials
4 trialsNCT00649584 2014-12-18
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Seagen Inc.
Phase 1 Terminated
NCT01026415 2014-12-18
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Seagen Inc.
Phase 1 Completed
NCT01026233 2014-12-12
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
Seagen Inc.
Phase 1 Completed